ClinicalTrials.gg
Active, not recruitingNCT06003426Updated Mar 24, 2026

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of BMS-986278 and BMS-986278 Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 390 sites in 33 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,255
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 2 of them phase 3. Idiopathic Pulmonary Fibrosis · Bristol-Myers Squibb.

Enrollment
2nd of 10
1,255 · median 100
Started
2023
with 2 others
Phase 3
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 3, and was the 9th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • BMS-986278
  • LPA1 antagonist
  • IPF
  • Pulmonary fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with IPF aged ≥ 40 years at the time of signing the .
  • Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia.
  • If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
  • If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
  • Women who are of must have a highly effective form of and must provide a negative urine/serum pregnancy test.
  • Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Exclusion criteria

Exclusion Criteria

  • History of stroke or within 3 months prior to screening.
  • Participants who exhibit symptoms of heart failure at rest.
  • Participants who have a current or a previous malignancy with less than 2 years free of recurrence or a that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.
  • Other protocol-defined Inclusion/Exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,255 participants (actual)

Study arms

  • Experimental
    BMS-986278 Dose 1

    Drug: BMS-986278

  • Experimental
    BMS-986278 Dose 2

    Drug: BMS-986278

  • Placebo comparator
    BMS-986278 Placebo

    Drug: BMS-986278 Placebo

Interventions

  • Specified dose on specified days

    Also known as: Admilparant

  • DrugBMS-986278 Placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants that experience spontaneous syncopal events

    Cohort 1

    Time frame: At approximately 4 weeks

  2. Absolute change from baseline in forced vital capacity (FVC) measured in mL

    Cohort 2

    Time frame: Up to Week 52

Secondary outcomes

  1. Number of participants who discontinued treatment due to any low BP-related Adverse Events

    Cohort 1

    Time frame: Up to approximately 3 years

  2. Disease progression

    Cohort 2 Disease progression will be measured by the time to first disease progression event in at least 1 of the following parameters: * Absolute percent predicted forced vital capacity (ppFVC) decline of ≥ 10% from baseline * Acute exacerbation of pulmonary fibrosis * Respiratory-related hospitalization * All-cause mortality

    Time frame: Up to approximately 3 years

  3. Change from baseline in Living with Pulmonary Fibrosis Questionnaire (L-PF) cough domain score

    Cohort 2

    Time frame: Up to Week 52

  4. Change from baseline in L-PF dyspnea domain score

    Cohort 2

    Time frame: Up to Week 52

  5. Change from baseline in walking distance measured in 6-minute walk test (6MWT)

    Cohort 2

    Time frame: Up to Week 52

  6. Time to the first occurrence of any of the components of the composite endpoint: time to first acute exacerbation of pulmonary fibrosis, first Respiratory-related hospitalization, or all-cause mortality

    Cohort 2

    Time frame: Up to approximately 3 years

  7. Time to absolute percent ppFVC decline of ≥ 10% from baseline

    Cohort 2

    Time frame: Up to approximately 3 years

  8. Time to first acute exacerbation of pulmonary fibrosis

    Cohort 2

    Time frame: Up to approximately 3 years

  9. Time to first Respiratory-related hospitalization

    Cohort 2

    Time frame: Up to approximately 3 years

  10. Time to first pulmonary fibrosis-related hospitalization

    Cohort 2

    Time frame: Up to approximately 3 years

  11. Time to death

    Cohort 2

    Time frame: Up to approximately 3 years

  12. Change from baseline in L-PF fatigue domain score

    Cohort 2

    Time frame: Up to Week 52

  13. Change from baseline in L-PF impacts module score

    Cohort 2

    Time frame: Up to Week 52

  14. Change from baseline in cough numeric rating scale (NRS)

    Cohort 2

    Time frame: Up to Week 52

  15. Change from baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) health utility index score

    Cohort 2

    Time frame: Up to Week 52

  16. Change from baseline in EQ-5D-5L visual analog scale score

    Cohort 2

    Time frame: Up to Week 52

  17. Rate of decline from baseline in FVC (mL)

    Cohort 2

    Time frame: Up to Week 52

  18. Rate of decline in ppFVC from baseline

    Cohort 2

    Time frame: Up to Week 52

  19. Change in ppFVC from baseline

    Cohort 2

    Time frame: Up to Week 52

  20. Proportion of participants with absolute decline in ppFVC ≥10%

    Cohort 2

    Time frame: Up to Week 52

  21. Proportion of participants with relative decline in ppFVC ≥10%

    Cohort 2

    Time frame: Up to Week 52

  22. Change from baseline in single-breath diffusing capacity of the lung for carbon monoxide (DLCO SB) (corrected for hemoglobin) (mL/min/mm Hg)

    Cohort 2

    Time frame: Up to Week 52

  23. Change in percent predicted single breath diffusing capacity of the lung for carbon monoxide (ppDLCO SB) (corrected for hemoglobin) from baseline

    Cohort 2

    Time frame: Up to Week 52

  24. Change from baseline in quantitative lung fibrosis (QLF) score via high-resolution computed tomography (HRCT)

    Cohort 2

    Time frame: Up to Week 52

  25. Number of participants with Adverse Events (AEs)

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  26. Number of participants with Serious AEs (SAEs)

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  27. Number of participants with AEs leading to early discontinuation of investigational medicinal product (IMP)

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  28. Number of participants with AEs related to IMP

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  29. Number of treatment-emergent deaths

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  30. Number of participants with clinical laboratory abnormalities

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  31. Number of participants with electrocardiogram (ECG) abnormalities

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

  32. Number of participants with vital sign abnormalities

    Cohorts 1 and 2

    Time frame: Up to 28 days after last dose

07

Study locations

390 sites
  • Local Institution - 0189
    Birmingham, Alabama 35294, United States
  • Local Institution - 0361
    Phoenix, Arizona 85013-4220, United States
  • Local Institution - 0396
    La Jolla, California 92037-1027, United States
  • Local Institution - 0193
    Los Angeles, California 90033-5313, United States
  • Local Institution - 0398
    Los Angeles, California 90095-3075, United States
  • Local Institution - 0389
    Orange, California 92868-3201, United States
  • Local Institution - 0405
    Sacramento, California 95817, United States
  • Local Institution - 0185
    San Francisco, California 94143-2202, United States
  • Local Institution - 0186
    Stanford, California 94305, United States
  • Local Institution - 0363
    Aurora, Colorado 80045, United States
  • Local Institution - 0194
    Denver, Colorado 80206, United States
  • Local Institution - 0175
    New Haven, Connecticut 06510, United States
  • Local Institution - 0151
    Newark, Delaware 19713-1337, United States
  • Local Institution - 0367
    Washington D.C., District of Columbia 20007-2113, United States
  • Local Institution - 0101
    Brandon, Florida 33511-5706, United States
  • Local Institution - 0436
    Clearwater, Florida 33765, United States
  • Local Institution - 0425
    DeBary, Florida 32713-1817, United States
  • Local Institution - 0079
    Gainesville, Florida 32610, United States
  • Local Institution - 0352
    Hialeah, Florida 33016, United States
  • Local Institution - 0370
    Kissimmee, Florida 34746-4654, United States
  • Local Institution - 0502
    Leesburg, Florida 34748-5077, United States
  • Local Institution - 0153
    Loxahatchee Groves, Florida 33411, United States
  • Local Institution - 0187
    Ocala, Florida 34471, United States
  • Local Institution - 0418
    Pensacola, Florida 32503-2670, United States
  • Local Institution - 0206
    St. Petersburg, Florida 33704, United States
  • Local Institution - 0364
    Tampa, Florida 33606, United States
  • Local Institution - 0372
    Dublin, Georgia 31021-2561, United States
  • Local Institution - 0178
    Chicago, Illinois 60611, United States
  • Local Institution - 0183
    Chicago, Illinois 60612-3841, United States
  • Local Institution - 0058
    Chicago, Illinois 60637, United States
  • Local Institution - 0085
    Maywood, Illinois 60153-3328, United States
  • Local Institution - 0325
    Peoria, Illinois 61637-0001, United States
  • Local Institution - 0180
    Iowa City, Iowa 522242-1009, United States
  • Local Institution - 0204
    Kansas City, Kansas 66160, United States
  • Local Institution - 0393
    Louisville, Kentucky 40202-1332, United States
  • Local Institution - 0354
    Baltimore, Maryland 21201-1544, United States
  • Local Institution - 0380
    Boston, Massachusetts 02114, United States
  • Local Institution - 0040
    Boston, Massachusetts 02135-2907, United States
  • Local Institution - 0472
    Ann Arbor, Michigan 48109-5000, United States
  • Local Institution - 0096
    Chesterfield, Missouri 63017-3425, United States
  • Local Institution - 0174
    St Louis, Missouri 63110-1010, United States
  • Local Institution - 0154
    Mount Kisco, New York 10549-3417, United States
  • Local Institution - 0433
    Durham, North Carolina 27710, United States
  • Local Institution - 0366
    Wilmington, North Carolina 28412, United States
  • Local Institution - 0368
    Winston-Salem, North Carolina 27103, United States
  • Local Institution - 0201
    Cincinnati, Ohio 45267-0595, United States
  • Local Institution - 0197
    Columbus, Ohio 43201, United States
  • Local Institution - 0417
    Toledo, Ohio 43608-2603, United States
  • Local Institution - 0181
    Oklahoma City, Oklahoma 73104-5417, United States
  • Local Institution - 0373
    Tulsa, Oklahoma 74133, United States
  • Local Institution - 0021
    Portland, Oregon 97239-3011, United States
  • Local Institution - 0067
    Hershey, Pennsylvania 17033-2360, United States
  • Local Institution - 0406
    Philadelphia, Pennsylvania 19104-5161, United States
  • Local Institution - 0388
    Philadelphia, Pennsylvania 19107-5109, United States
  • Local Institution - 0199
    Philadelphia, Pennsylvania 19140-5103, United States
  • Local Institution - 0202
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0346
    Wynnewood, Pennsylvania 19096-3432, United States
  • Local Institution - 0375
    Anderson, South Carolina 29621, United States
  • Local Institution - 0188
    Charleston, South Carolina 29425, United States
  • Local Institution - 0400
    Nashville, Tennessee 37204, United States
  • Local Institution - 0073
    Dallas, Texas 75235-5351, United States
  • Local Institution - 0377
    Dallas, Texas 75245-2017, United States
  • Local Institution - 0039
    Houston, Texas 77030-4202, United States
  • Local Institution - 0097
    Houston, Texas 77030, United States
  • Local Institution - 0029
    McKinney, Texas 75069, United States
  • Local Institution - 0048
    San Antonio, Texas 78229-4404, United States
  • Local Institution - 0027
    Salt Lake City, Utah 84108, United States
  • Local Institution - 0184
    Richmond, Virginia 23298, United States
  • Local Institution - 0191
    Everett, Washington 98208-6526, United States
  • Local Institution - 0362
    Seattle, Washington 98195, United States
  • Local Institution - 0131
    Mar del Plata, Buenos Aires 7600, Argentina
  • Local Institution - 0019
    Buenos Aires, B C1426ABO, Argentina
  • Local Institution - 0172
    Caba, B C1425FVH, Argentina
  • Local Institution - 0170
    Florida, B 1602, Argentina
  • Local Institution - 0286
    Mar del Plata, B 7600, Argentina
  • Local Institution - 0485
    Quilmes, Provincia de Buenos Aires, B 1878, Argentina
  • Local Institution - 0290
    San Juan Bautista, B 1853, Argentina
  • Local Institution - 0288
    Ciudad Autónoma Buenos Aires, C 1181, Argentina
  • Local Institution - 0287
    Godoy Cruz, M 5501, Argentina
  • Local Institution - 0013
    Mendoza, M 5500, Argentina
  • Local Institution - 0356
    Mendoza, M M5500, Argentina
  • Local Institution - 0330
    Rosario, S 2000, Argentina
  • Local Institution - 0169
    San Miguel de Tucumán, T T4000, Argentina
  • Local Institution - 0218
    Córdoba, X X5003DCE, Argentina
  • Local Institution - 0283
    Buenos Aires, C1056ABJ, Argentina
  • Local Institution - 0173
    Santa Fe, 3000, Argentina
  • Local Institution - 0209
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0239
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0210
    Brisbane, Queensland 4032, Australia
  • Local Institution - 0229
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0421
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0309
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0443
    Box Hill, Victoria 3128, Australia
  • Local Institution - 0420
    Frankston, Victoria 3199, Australia
  • Local Institution - 0419
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0385
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0458
    Salzburg, Salzburger Land 5020, Austria
  • Local Institution - 0409
    Linz, Upper Austria 4020, Austria
  • Local Institution - 0025
    Vienna, 1130, Austria
  • Local Institution - 0459
    Vienna, 1210, Austria

Showing the first 100 of 390 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Oct 2026, 36 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 22, 2023
StartActual
Sep 14, 2023
Primary completionEst.
Oct 6, 2026
CompletionEst.
Jun 4, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06003426
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Sep 14, 2023
Primary completion
Oct 6, 2026 (estimated)
Completion
Jun 4, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion